Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Artivion Inc. (AORT) Insider Trading Activity
Healthcare • Medical Devices • 1,500 employees
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Total Value
-$2,267,721.47
Total Shares
122,237
Average Trade Value
-$68,718.83
Most Active Insider
Mackin James P
Total Activity: $1,161,112
Largest Single Transaction
$455,027
by Mackin James P on Feb 24, 2025
30-Day Activity
2 Transactions
Volume: 2,100 shares
Value: $53,141
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Director
|
Mar 5, 2025 | 600 | $15,150 | 600 (+100.0%) | Purchase | |
Director
|
Mar 5, 2025 | 1,500 | $37,991 | 35,659 (+4.2%) | Purchase | |
Svp, General Counsel
Officer
|
Feb 28, 2025 | 23,416 | $10,000 | 173,215 (+13.5%) | Grant | |
Svp, Clinical Md Affair
Officer
|
Feb 28, 2025 | 18,398 | $10,000 | 98,243 (+18.7%) | Grant | |
Executive Vp, CFO
Officer
|
Feb 28, 2025 | 34,435 | $10,000 | 110,240 (+31.2%) | Grant | |
Chief Commercial Officer
Officer
|
Feb 28, 2025 | 24,301 | $10,000 | 184,932 (+13.1%) | Grant | |
President CEO
Officer
|
Feb 28, 2025 | 98,524 | $10,000 | 762,406 (+12.9%) | Grant | |
Vp, Chief Accounting Officer
Officer
|
Feb 28, 2025 | 6,297 | $10,000 | 137,438 (+4.6%) | Grant | |
Vp, Chief Accounting Officer
Officer
|
Feb 24, 2025 | 318 | $8,683 | 131,626 (-0.2%) | Sale | |
Vp, Chief Accounting Officer
Officer
|
Feb 24, 2025 | 485 | $13,243 | 131,141 (-0.4%) | Sale | |
Svp, Clinical Md Affair
Officer
|
Feb 24, 2025 | 672 | $18,350 | 81,091 (-0.8%) | Sale | |
Chief Commercial Officer
Officer
|
Feb 24, 2025 | 985 | $26,896 | 162,666 (-0.6%) | Sale | |
Svp, Clinical Md Affair
Officer
|
Feb 24, 2025 | 470 | $12,834 | 81,763 (-0.6%) | Sale | |
Svp, Clinical Md Affair
Officer
|
Feb 24, 2025 | 2,299 | $62,776 | 82,233 (-2.8%) | Sale | |
Svp, Clinical Md Affair
Officer
|
Feb 24, 2025 | 1,246 | $34,023 | 79,845 (-1.6%) | Sale | |
President CEO
Officer
|
Feb 24, 2025 | 6,812 | $186,008 | 668,778 (-1.0%) | Sale | |
President CEO
Officer
|
Feb 24, 2025 | 4,896 | $133,690 | 663,882 (-0.7%) | Sale | |
President CEO
Officer
|
Feb 24, 2025 | 16,664 | $455,027 | 689,374 (-2.4%) | Sale | |
President CEO
Officer
|
Feb 24, 2025 | 13,784 | $376,386 | 675,590 (-2.0%) | Sale | |
Svp, General Counsel
Officer
|
Feb 24, 2025 | 490 | $13,380 | 152,259 (-0.3%) | Sale | |
Chief Commercial Officer
Officer
|
Feb 24, 2025 | 2,846 | $77,713 | 164,242 (-1.7%) | Sale | |
Chief Commercial Officer
Officer
|
Feb 24, 2025 | 2,035 | $55,568 | 160,631 (-1.3%) | Sale | |
Svp, General Counsel
Officer
|
Feb 24, 2025 | 810 | $22,118 | 151,449 (-0.5%) | Sale | |
Svp, General Counsel
Officer
|
Feb 24, 2025 | 1,650 | $45,055 | 149,799 (-1.1%) | Sale | |
Svp, General Counsel
Officer
|
Feb 24, 2025 | 2,385 | $65,125 | 152,749 (-1.6%) | Sale | |
Executive Vp, CFO
Officer
|
Feb 24, 2025 | 3,259 | $88,990 | 75,805 (-4.3%) | Sale | |
Vp, Chief Accounting Officer
Officer
|
Feb 24, 2025 | 814 | $22,227 | 131,944 (-0.6%) | Sale | |
Chief Commercial Officer
Officer
|
Feb 24, 2025 | 591 | $16,138 | 163,651 (-0.4%) | Sale | |
Vp, Chief Accounting Officer
Officer
|
Feb 24, 2025 | 1,706 | $46,584 | 132,758 (-1.3%) | Sale | |
Svp, General Counsel
Officer
|
Dec 11, 2024 | 4,035 | $122,059 | 157,897 (-2.6%) | Sale | |
Svp, General Counsel
Officer
|
Dec 11, 2024 | 4,035 | $121,050 | 153,862 (-2.6%) | Sale | |
Vp, Chief Accounting Officer
Officer
|
Dec 6, 2024 | 4,329 | $128,398 | 135,660 (-3.2%) | Sale | |
VP Regulatory
Officer
|
Dec 4, 2024 | 7,618 | $228,540 | 33,503 (-22.7%) | Sale |